## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 5.3% in mid entry zone (3.0-6.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (3.5%) confirms momentum alignment. Strong momentum (+3.5% 5-day acceleration). Outperforming sector by 6.8%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($24.69)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. F m Investments LLC Lowers Position in ACADIA Pharmaceuticals Inc. $ACAD**
- Source: MarketBeat | 20251204T231009 | Somewhat-Bullish | Relevance: 100%
- F m Investments LLC reduced its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 29.5% in the second quarter of 2025, now holding 48,449 shares valued at $1.045 million. Despite this reduction, other large institutional investors like Norges Bank and Prudential Financial Inc. increased their positions, with institutional ownership of the stock standing at 96.71%. ACADIA Pharmaceuticals exceeded Q3 earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $28.83.

**2. Should ACADIA’s Earnings Beat and Conference Highlights Require Action From ACADIA Pharmaceuticals (ACAD) Investors?**
- Source: Simply Wall Street | 20251204T000938 | Somewhat-Bullish | Relevance: 100%
- ACADIA Pharmaceuticals recently presented at Citi’s Annual Global Healthcare Conference 2025, emphasizing its progress in CNS and rare disease therapies. Strong Q3 earnings and positive analyst commentary on Nuplazid and Daybue sales have brought ACADIA's growth into focus. While recent results reinforce confidence, the company still faces concentration risk with Nuplazid and needs pipeline success for future growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |
| 2025-11-06 | RBC Capital | $32 | $34 | -6% |
| 2025-11-06 | Needham | $29 | $28 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |
| 2025-11-06 | RBC Capital | main | Outperform |
| 2025-11-06 | Needham | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.0%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +3.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.67 |
| 52W Range | $13.40 - $28.35 |
| Short Interest | 8.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.0 |
| Current P/E | 32.6 |
| YoY Growth | -1.2% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.8% to 5.3% (+3.5% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 89th percentile. MRS_5 at 3.5% confirms short-term momentum alignment. Outperforming sector by 6.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 73, risk of mean reversion. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 5.31% (CS: 90) | Strong |
| RSI_14 | 72.6 | Overbought |
| MACD Histogram | 0.24 | Bullish |
| vs SMA20 | 1.106x | Above |
| vs SMA50 | 1.179x | Above |
| vs SMA200 | 1.262x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.55
- **Stop Loss:** $24.69 (7.0% risk)
- **Target:** $29.34 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 268
- **Position Value:** $7,115.40
- **Portfolio %:** 7.12%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*